Tecotabart vedotin, which also consists of a humanized anti-CLDN18.2 IgG1 mAb, a cleavable linker and an MMAE payload, demonstrated superior antitumor efficacy to the mouse/human chimeric mAb zolbetuximab in a preclinical xenograft model of gastric cancer (Huang W et al., 2022). This evidence concerns the gene CLDN18 and gastric cancer.